Drugs / GP40081
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04226105 | Jan → Sep 2020 | type 2 diabetes mellitus | Geropharm | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04184492 | Apr → Jun 2019 | — | Geropharm | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GP-40081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04184492 ↗ |
| Modality | Protein / enzyme biologic | “soluble insulin aspart/protamine-crystallised insulin aspart” NCT04226105 ↗ |
| Route | Subcutaneous | “Single subcutaneous administration of GP-40081” NCT04184492 ↗ |